Sudeep Pharma Q4 FY26 Earnings Call — Analysis (NSE: SUDEEPPHRM)

Sudeep Pharma reports 27.9% YoY revenue growth to ₹642.3 Cr in FY26, driven by 62% jump in specialty ingredients; battery materials commercial orders begin and greenfield facility enters customer qualification phase.

22 May 2026 · Analysis by Alpha Inflection

Result quality: stable — Results context unavailable. Management sentiment: optimistic.

The take

FY26 Revenue ₹642.3 Cr ( +27.9% YoY ) . New guidance — FY27 battery materials sales volume… ~2,500 metric tons . New story: Greenfield unlocking high-value molecules .

Results

FY26 revenue ₹642.3 Cr (+27.9% YoY), EBITDA ₹221.9 Cr (+16.8% YoY), margin 34.6% (vs 37.8% FY25); Q4FY26 revenue ₹182.3 Cr (+15.7% YoY), EBITDA ₹62.6 Cr, margin 34.3%.

Financial highlights

Guidance

FY27 pharma food nutrition revenue growth to exceed 10%, specialty ingredients to maintain similar momentum, consolidated EBITDA margin to return to 37-38%, and battery materials Phase 1 (25,000 MTPA) on track for April 2027.

What management committed to

• Management targets reducing net working capital days to 150–160 days within FY27. — 150–160 days, FY27
• [Battery materials plant at Dahej] Phase 1 capacity of 25,000 metric tons per year will be commissioned by April 2027. — 25,000 metric tons per year, FY28
• [Sudeep Advanced Materials] expects to sell approximately 2,500 metric tons of battery-grade iron phosphate in FY27. — ~2,500 metric tons, FY27
• [Pharma food and nutrition segment] revenue growth in FY27 will exceed 10%, faster than the 10% growth recorded in FY26. — over 10%, FY27
• [Consolidated] EBITDA margin will return to around 37–38% in FY27, similar to FY24–25 levels. — 37–38%, FY27
• Customer qualification for the [greenfield manufacturing facility] will take six to 12 months from now. — 6–12 months, six to 12 months
• [Bisglycinate products] will be produced at commercial scale in FY27. — FY27
• The core business (excluding battery) can scale to approximately ₹1,000–₹1,200 crores in revenue without any incremental capex in the existing product portfolio. — ₹1,000–₹1,200 Cr

Key themes

Specialty surge, greenfield ramp, battery orders

How the narrative shifted

• Specialty ingredients driving growth: Specialty revenue surged 62% to contribute 44% of FY26 revenue, driven by encapsulation and premix approvals with global leaders, and is expected to maintain strong momentum.
• Greenfield unlocking high-value molecules: The new greenfield facility has completed internal validation and will add capacity for glycinates, gluconates, and citrates, addressing capacity constraints and supporting pharma segment growth.
• Battery materials China+1 commercial breakthrough: Customer engagement rapidly advancing with 6 customers completing commercial validation and initial orders of 700 MT; Phase 1 on track for April 2027 to capture supply chain diversification away from China.
• International expansion and on-ground teams: Investments in North America and European commercial teams, warehousing, and NSS leadership are expected to convert approvals into revenue and improve wallet share with large global accounts.
• Margin recovery to historical levels: Management expects one-time costs (air freight, LPG premium, pre-hiring) to reverse and operating leverage from new teams to lift consolidated EBITDA margin back to 37–38% in FY27.
• Working capital normalization: Inventory build for strategic supply security and export orders pushed working capital days to 213; management targeting 150–160 days by FY27 end through tighter controls.

Operational commentary

• Specialty ingredients revenue grew 62% YoY to ₹280 Cr, contributing 44% of FY26 revenue (up from 34% in FY25); growth led by encapsulation and premix categories, with approvals from top global bakery and infant nutrition companies.
• Battery materials (SAM): 42 customers in qualification pipeline – 22 lab validation, 14 pilot-scale, 6 completed commercial validation and in active off-take discussions; initial commercial orders of ~700 MT received in last month; Phase 1 capacity of 25,000 MTPA on track for commissioning by April 2027 at Dahej.
• Greenfield manufacturing facility: internal production validation and qualification completed; customer approval process initiated with expected timelines of 6–12 months; will significantly enhance capacity for high-value molecules (glycinate, gluconate, citrate).
• Pharma food nutrition segment revenue grew 10% YoY in FY26, with volume growth >20% but mix shift and delayed phosphate price pass-through (effective only from Q1/Q2 FY27) held back value growth; capacity constraints expected to ease with greenfield.
• International commercial build-out: 51 new customer approvals won in FY26; on-ground teams established in North America and Europe; NSS integration progressing, new business head (Mattias Fredrickson) appointed to drive European expansion in infant/medical nutrition.
• Working capital days increased to 213 (from 184) driven by strategic inventory build (raw material phosphoric acid ₹41 Cr, finished goods ₹37 Cr for upcoming export orders); management targeting 150–160 days by end of FY27 through tighter inventory and receivables management.
• FY26 gross capex: ₹127 Cr (greenfield ₹80 Cr, SAM land ₹34 Cr, maintenance ₹13 Cr); FY27 core capex light (~₹10 Cr for greenfield completion + ₹15 Cr maintenance) with battery capex to be funded separately.

Analyst Q&A

• Q. Clarification on sharp QoQ increase in other expenses.

  Ketan Vyas explained one-time items: ~₹3 Cr CSR expenditure, ₹1.5 Cr LPG premium due to shortages, and ₹2 Cr air freight for a large customer due to production delays; all expected to reverse going forward.

• Q. Request for revenue outlook for FY27–FY28.

  Shanil Bhayani did not provide direct revenue guidance but stated comfort that momentum will continue, with pharma food nutrition growing faster than 10% and specialty tracking similar growth.

• Q. Quantification of realisation premium for new molecules (bisglycinate) and battery chemicals versus existing portfolio.

  Shanil Bhayani declined to give specific numbers citing competitive sensitivity and said margin details would not be disclosed too publicly, though indicated bisglycinate realisation is ~4x current portfolio.

Research and educational content only. Not investment advice.